OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cardiology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
LIPC variant in combined hypocholesterolaemia	939
Antibody treatment to deplete transthyretin amyloid deposits in the heart	457
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	455
Intravascular imaging improves outcomes	403
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	398
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	394
Genetics and mechanisms of thoracic aortic disease	377
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	368
Optimizing cardiovascular pharmacotherapy in older adults with frailty	308
The City Heartbeat Index as a benchmarking tool for urban cardiovascular health	302
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	299
Takotsubo syndrome: pathophysiological insights and innovations in patient care	297
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	288
Alternative defibrillation strategies improve outcomes	262
Think Aorta: aortic dissection awareness and perspectives from the patient	247
Detection of subclinical hypertrophic cardiomyopathy	247
HFpEF and MASLD: converging mechanisms and clinical implications	237
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	232
Drug-coated balloon angioplasty for coronary and peripheral artery disease: latest evidence and clinical indications	226
Defining iron deficiency in patients with heart failure	226
Base editing and silencing of PCSK9 shows clinical promise in humans	225
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice	223
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	219
A fatty acid from mother’s milk drives cardiomyocyte maturation in newborn mice	203
Hallmarks of cardiovascular ageing	203

Preparticipation screening reduces SCD in young athletes	195
Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes	163
No benefit of apoA-I infusion after myocardial infarction	159
Identifying leukocyte phenotypes by scRNA-seq to predict cardiovascular risk	156
Catheter ablation improves outcomes in patients with AF and end-stage HF	153
Colchicine in acute coronary syndromes: the present and the possible future	146
Increased degradation of desmosomal proteins in ACM	139
CSDE1 regulates LDL receptor levels	137
Cardiac lymphatic dysfunction and repair in cardiovascular disease	136
LDL-cholesterol lowering with obicetrapib	129
Targeting immune cell recruitment in atherosclerosis	128
Reactive oxygen species in hypertension	124
Tailored therapeutics for cardiomyopathies	124
Decongestion in heart failure: medical and device therapies	122
The oral microbiome in the pathophysiology of cardiovascular disease	121
Extracellular matrix in vascular homeostasis and disease	121
Graded exercise therapy should not be recommended for patients with post-exertional malaise	113
Modelling pre-eclampsia and its cardiovascular effects	111
Donor macrophages influence rejection of transplanted hearts	111
Cardiac sarcomere turnover by unidirectional replacement of proteins	109
Reply to ‘Graded exercise therapy should not be recommended for patients with post-exertional malaise’	109
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine	106
Bempedoic acid prevents cardiovascular events in statin-intolerant patients	106
Promising novel siRNA for the treatment of hypertension	104
Semaglutide is beneficial in patients with HFpEF and obesity	102
Calculation methods for LDL cholesterol are evolving tools for accuracy in lipidology	100
RNA interference lowers triglyceride levels	99
Evidence does not support the reduction of added sugar intake from all food sources	97
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials	96
Local calcium dynamics and signalling in cardiomyocytes	95
Global epidemiology of heart failure	94
An epigenome editing approach induces durable silencing of Pcsk9	92
Single-cell profiles of CHD and CM	91
BP management with a village-doctor-led strategy	88
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight	86
Simvastatin protects against endothelial dysfunction via epigenetic mechanisms	84
The role of the molecular autopsy in sudden cardiac death in young individuals	83
Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	81
Development of a miniature, bioresorbable, light-activated pacemaker	77
The gut metabolite imidazole propionate is a potential biomarker of and therapeutic target for atherosclerosis	76
Tricuspid valve disease: updates on diagnostic imaging and intervention	73
Heart transplantation: advances in expanding the donor pool and xenotransplantation	70
Efferocytosis in atherosclerosis	70
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	69
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target	69
CNR1 antagonism attenuates cannabis-induced atherosclerosis	68
Low alcohol intake might lower CVD risk by reducing stress-related brain activity	67
Baxdrostat beneficial in uncontrolled or resistant hypertension	65
PCSK9 inhibition for primary prevention of cardiovascular events	63
Gene–environment interactions in the pathogenesis of cardiovascular disease	59

Gut bacteria can break down cholesterol	58
Cardiovascular benefits of fermented foods and beverages: still up for debate	57
Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy	56
New insights into dietary cholesterol absorption	56
Molecular gatekeepers of endogenous adult mammalian cardiomyocyte proliferation	54
Renal denervation for hypertension	54
Stenting for post-thrombotic syndrome	53
Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis	52
Cardiovascular disease and cancer: shared risk factors and mechanisms	51
Mechanisms and treatment of pulmonary arterial hypertension	50
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	48
Improving medication adherence in cardiovascular disease	48
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis	47
Cardiac optogenetics: controlling the heart with light	42
The environmental exposome in heart failure risk and progression	41
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia	41
Integration of cardiovascular and mental health: from concepts to the clinic	40
Synthetic ion channel modulator reverses sodium channel dysfunction linked to cardiac arrhythmias	40
Transcriptional regulation in heart development, disease and regeneration: reassessing the fetal gene hypothesis	39
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention	38
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	38
Epigenetic editing in cardiovascular medicine: moving beyond the hype	37
Metabolites matter for gut microbiota as a modifiable risk factor in cardiovascular diseases	36
The need for increased pragmatism in cardiovascular clinical trials	36
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications	35
Heart failure and obesity: novel insights leading to new treatment paradigms	35
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	34
The cardiac parasympathetic system has two parallel circuits	34
Black In Cardio: promoting diversity and representation in the cardiovascular field	33
Artificial intelligence-enhanced echocardiography in cardiovascular disease management	33
Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women	33
Colchicine in patients with cardiovascular disease	33
Gout flares can precede cardiovascular events	33
Inhibiting aldosterone synthase reduces blood pressure	31
Sotatercept as add-on therapy for advanced PAH	31
Phase separation of protein kinase A: a new paradigm in cardiac regulation?	31
ASGR1 inhibition stimulates cholesterol excretion	30
Age-induced senescence impairs the neurovascular interface in the heart	30
Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition	29
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	28
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	27
Consequences of ionizing radiation exposure to the cardiovascular system	27
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	27
Surgery safer than endovascular therapy for CLTI	27
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	27
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials	27
Imaging cAMP nanodomains in human iPSC-derived cardiomyocytes	26
A distinct platelet differentiation pathway is involved in age-related thrombocytosis	26
Characterization of the F8 gene: a silver lining in a dark cloud	26
Preserving the future of heart transplantation	26
Building the Australian Cardiovascular disease Data Commons	25
Vagal mechanoreceptors in the heart sense changes in blood volume	24
An ex vivo perfusion platform for the testing of cardiovascular interventional devices	24
Effects of lifestyle factors on leukocytes in cardiovascular health and disease	24
Publisher Correction: Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	24
Genome editing prevents hypertrophic cardiomyopathy in mice	24
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies	24
Leadless and extravascular cardiac resynchronization therapy: the future for CRT?	24
A role for lipophagy in atherosclerosis	23
Implementing LGBTQ-inclusive policies for cardiology practice and the workforce	22
Alain Cribier (1945–2024)	22
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	22
Mind the gap: sex-related differences in cardiovascular disease	21
Charting the future of cardiology with large language model artificial intelligence	21
Mapping the functions of IgM antibodies in atherosclerotic cardiovascular disease	20
Unravelling the genetic heart–brain connection using MRI	20
Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity	20
Current concepts and novel targets for antiplatelet therapy	20
Non-coding RNAs in lipid metabolism and their roles in atherosclerosis	19
Single-cell transcriptomics for the assessment of cardiac disease	18
Cardiac epigenome in heart development and disease	18
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	18